Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

986
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
986
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

17
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic...
17
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

7
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
7
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

16
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
16
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

11
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
11

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered Cytokine Profile in Clinically Suspected Seronegative Autoimmune Associated Epilepsy.

medRxiv : the preprint server for health sciences·2024
Same author

Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

MMWR. Morbidity and mortality weekly report·2022
Same author

An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route.

Vaccine·2018
Same author

Improving communication with families in the intensive care unit.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2017
Same author

Pre-exposure rabies prophylaxis: a systematic review.

Bulletin of the World Health Organization·2017
Same author

Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.

Bioscience reports·2015

Related Experiment Video

Updated: Apr 24, 2026

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K

Metformin-associated lactic acidosis.

Deborah Briggs1

  • 1University of Hull.

Emergency Nurse : the Journal of the RCN Accident and Emergency Nursing Association
|September 5, 2014
PubMed
Summary
This summary is machine-generated.

Metformin, a common diabetes drug, can cause severe lactic acidosis in some patients, especially those with underlying health issues. This case highlights the importance of considering metformin-associated lactic acidosis in patients presenting with metabolic acidosis and related symptoms.

Keywords:
Metforminrhabdomyolysistype 2 diabetes mellitus

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
05:58

Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells

Published on: February 24, 2026

614

Related Experiment Videos

Last Updated: Apr 24, 2026

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
05:58

Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells

Published on: February 24, 2026

614

Area of Science:

  • Emergency Medicine
  • Clinical Pharmacology
  • Nephrology

Background:

  • Metformin is a widely prescribed oral antihyperglycemic agent for type 2 diabetes mellitus.
  • Metformin-associated lactic acidosis (MALA) is a rare but serious complication.
  • Distinguishing MALA from other causes of metabolic acidosis, such as rhabdomyolysis, is critical for appropriate management.

Purpose of the Study:

  • To present a case of a patient with type 2 diabetes mellitus who developed severe metformin-associated lactic acidosis.
  • To discuss the diagnostic challenges in differentiating MALA from rhabdomyolysis.
  • To emphasize the importance of recognizing risk factors and clinical presentation of MALA.

Main Methods:

  • Case report of a 68-year-old female patient presenting to the emergency department.
  • Clinical assessment including vital signs, laboratory investigations, and patient history.
  • Differential diagnosis consideration between rhabdomyolysis and MALA.

Main Results:

  • The patient presented with hypoglycemia, hypotension, unconsciousness, and severe metabolic acidosis.
  • Initial suspicion of rhabdomyolysis was revised to metformin-associated lactic acidosis after further evaluation.
  • The patient's condition improved with discontinuation of metformin and supportive care.

Conclusions:

  • Metformin-associated lactic acidosis should be considered in patients with type 2 diabetes mellitus presenting with unexplained metabolic acidosis, especially if risk factors are present.
  • Early recognition and prompt management are crucial for improving outcomes in MALA.
  • Awareness of MALA can prevent misdiagnosis and delayed treatment.